Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL9539322 | 0.94 | ALDH1A1 (0.33) | KCNN4ALDH1A1 | |
| Phenylboronic Acid SCHEMBL988759 | 0.87 | CA4 (0.44) | — | |
| SCHEMBL4633672 | 0.87 | PTPN1 (0.40) | — | |
| SCHEMBL30139540 | 0.85 | KIF11 (0.40) | ALDH1A1 | |
| SCHEMBL16975529 | 0.85 | KIF11 (0.37) | TSHRALDH1A1 | |
| SCHEMBL29518677 | 0.83 | — | — | |
| SCHEMBL8987735 | 0.82 | ESR1 (0.41) | KCNN4TSHRALDH1A1 | |
| SCHEMBL2816468 | 0.80 | ALDH1A1 (0.39) | KCNN4ALDH1A1 | |
| Benzene SCHEMBL4593432 | 0.80 | TSHR (0.38) | TSHRALDH1A1 | |
| SCHEMBL28872444 | 0.80 | KCNN4 (0.48) | KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109621863-A | One kind being used for the brominated reaction unit in biphenyl derivatives Bian position and bromination process | 临海市华南化工有限公司 | 2019-04-16 | — | — | CN | claimed |
| WO-2010067912-A1 | METHODS FOR PREPARING BIPHENYL BENZOIC ACID DERIVATIVES | PHARMACOSTECH CO., LTD. (KR) | 2010-06-17 | — | — | WO | claimed |
| CN-1666989-A | Candesartan Cilexetil preparing process | SHANXI AID PHARMACEUTICAL CO L (CN) | 2005-09-14 | — | — | CN | claimed |
| EP-1032557-B1 | METHOD FOR PREPARING BROMOMETHYL-BIPHENYL DERIVATIVES | SANOFI SYNTHELABO (FR) | 2003-09-10 | — | — | EP | claimed |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | claimed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | claimed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | claimed |
| US-6214999-B1 | A BROMINATING AGENT IS REACTED IN A 2 PHASE MEDIUM, UNDER EFFECT PHOTO-IRRADIATION WITH BIPHENYL DERIVATIVE | SANOFI-SYNTHELABO (FR) | 2001-04-10 | — | — | US | claimed |
| EP-1032557-A1 | METHOD FOR PREPARING BROMOMETHYL-BIPHENYL DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-09-06 | — | — | EP | claimed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | claimed |
| EP-0479903-B1 | SUBSTITUTED IMIDAZOLES USEFUL AS ANGIOTENSIN II BLOCKERS | DU PONT (US) | 1996-02-21 | — | — | EP | claimed |
| EP-0685467-A1 | NOVEL PYRIMIDINE DERIVATIVE AND MEDICINAL COMPOSITION | NKK CORPORATION (JP) | 1995-12-06 | — | — | EP | claimed |
| EP-0253310-B1 | Angiotensin II receptor blocking imidazoles | DU PONT (US) | 1994-10-26 | — | — | EP | claimed |
| EP-0479892-A1 | FUSED-RING ARYL SUBSTITUTED IMIDAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0479903-A1 | SUBSTITUTED IMIDAZOLES. | DU PONT (US) | 1992-04-15 | — | — | EP | claimed |
| WO-1991000277-A1 | SUBSTITUTED IMIDAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-10 | — | — | WO | claimed |
| WO-1991000281-A2 | FUSED-RING ARYL SUBSTITUTED IMIDAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-10 | — | — | WO | claimed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | claimed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | claimed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | KCNN4 262/4885TSHR 430/4885ALDH1A1 1169/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | KCNN4 262/4885TSHR 430/4885ALDH1A1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.